Abstract: The present disclosure relates to a method for detecting a prostate cancer related biomarker, including contacting the diluted sample with a modulating agent selected from a group consisting of sodium; 3-hydroxy-4-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-1-sulfonate, sodium; 3-hydroxy-4-[(1-hydroxynaphthalen-2-yl)diazenyl]-7-nitronaphthalene-1-sulfonate, triisopropylsilane, and iron(III) chloride, and a luminescent label to obtain a measurement sample. Then, the measurement sample is incubated for a period of time and excited thereafter. Time-resolved luminescence signal of the label in the measurement sample is measured, leading to an increased likelihood of prostate cancer of the human subject if the luminescence signal is at least 50% higher than for a control sample from a human subject without prostate cancer.

Abstract: The invention relates to a method for processing black liquor soap, particularly to a method for producing and recovering fatty acid esters and resin acids from black liquor soap. The method is based on a catalytic selective esterification of the soap.

Abstract: The present disclosure relates to a method for detecting a prostate cancer related biomarker, including contacting the diluted sample with a modulating agent selected from a group consisting of sodium; 3-hydroxy-4-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-1-sulfonate, sodium; 3-hydroxy-4-[(1-hydroxynaphthalen-2-yl)diazenyl]-7-nitronaphthalene-1-sulfonate, triisopropylsilane, and iron(III) chloride, and a luminescent label to obtain a measurement sample. Then, the measurement sample is incubated for a period of time and excited thereafter. Time-resolved luminescence signal of the label in the measurement sample is measured, leading to an increased likelihood of prostate cancer of the human subject if the luminescence signal is at least 50% higher than for a control sample from a human subject without prostate cancer.

Abstract: The present invention relates to a water treatment method for removing sulfur substances using a solid material comprising 2-amino-2-deoxy-d-glucopyranose structural units, wherein the solid material is combined with an acidic aqueous medium containing sulfur substances so that the negatively charged sulfur substances can be bound to the solid material and subsequently be removed from the aqueous medium by separating the solid material. The present invention can be used to remove sulfur substances such as sulfate, bisulfate, sulfite, bisulfite, metabisulfite, sulfide, bisulfide and thiosulfate from an aqueous medium.

Abstract: A method for collecting metals from a solution, in which method solid insoluble or sparingly soluble bisphoshonate of formula I is mixed with the solution, whereby metals possibly present in the solution react with the bisphosphonate, and the bisphosphonate together with the metals reacted with it is separated from the solution. The method can be used for collecting metals e.g. from waste water or from household water.

Abstract: Novel methods for treating and preventing acute and/or chronic pancreatitis are described. Additionally, novel methods for inducing liver regeneration are described. The methods may comprise administering to a patient an effective amount of a metabolically stable analogue of spermidine and/or spermine. Preferred compounds for use in the methods may include 1-methylspermidine, 1-methylspermine and 1,12-dimethylspermine.

Abstract: A compound of formula (I), wherein X, R1, R2 and R3 are as defined in the disclosure, or a pharmaceutically acceptable salt or ester thereof, useful as a prolyl oligopeptidase inhibitor. The compounds can be used for the treatment of diseases or conditions where prolyl oligopeptidase inhibitors are indicated to be effective, for example for the treatment of neurodegenerative diseases, such as Alzheimer's disease and senile dementia.

Abstract: Novel methods for treating and preventing acute and/or chronic pancreatitis are described. Additionally, novel methods for inducing liver regeneration are described. The methods may comprise administering to a patient an effective amount of a metabolically stable analogue of spermidine and/or spermine. Preferred compounds for use in the methods may include 1-methylspermidine, 1-methylspermine and 1,12-dimethylspermine.

Abstract: The object of the invention are novel halogen substituted methylenebisphosphonic acid anhydrides, ester anhydrides, amide anhydrides, and ester amide anhydrides, processes for the preparation of these novel compounds, as well as pharmaceutical preparations comprising these novel compounds.

Abstract: The invention relates to novel methylenebisphosphonic acid ester amide derivatives of general formula (I), in which formula W.sup.1, W.sup.2, W.sup.3 and W.sup.4 are independently the group OR.sup.1 or the group NR.sup.2 R.sup.3 wherein R.sup.1, R.sup.2 and R.sup.3 independently are hydrogen or straight or branched, optionally unsaturated C.sub.1 -C.sub.22 -alkyl, optionally substituted, optionally unsaturated C.sub.3 -C.sub.10 -cycloalkyl, aryl, aralkyl or silyl SiR.sub.3, or the groups R.sup.2 and R.sup.3 form together with the adjacent nitrogen atom a 3 to 10-membered saturated, partly saturated or aromatic heterocyclic ring, wherein in addition to the nitrogen atom, there may be one or two heteroatoms from the group N, O and S, provided that in formula (I) at least one of the groups W.sup.1, W.sup.2, W.sup.3 and W.sup.4 is hydroxy and at least one of the groups W.sup.1, W.sup.2, W.sup.3 and W.sup.4 is amino group NR.sup.2 R.sup.3, Q.sup.1 and Q.sup.

Abstract: Novel pharmaceutically active bisphosphonic acid derivatives of formula (I), in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently are C.sub.1 -C.sub.22 -alkyl, C.sub.2 -C.sub.22 -alkenyl, C.sub.2 -C.sub.22 -alkynyl, C.sub.3 -C.sub.10 -cycloalkyl, C.sub.3 -C.sub.10 -cycloalkenyl, aryl, aralkyl, silyl and hydrogen, and R.sup.4 is different from hydrogen, Q.sup.1 is hydrogen, fluorine, chlorine, bromine or iodine, and Q.sup.2 is chlorine, bromine or iodine, including the stereoisomers, such as the geometrical isomers and optically active isomers, of the compounds, as well as the pharmaceutically acceptable salts of the compounds.